| Literature DB >> 29996808 |
Valérie Demange1, Denis Zmirou-Navier2, Abraham Bohadana3, Pascal Wild4.
Abstract
BACKGROUND: The natural history of airway inflammation and symptoms in occupations at risk of asthma is still not fully understood. We aimed to study the evolution during apprenticeship of inflammation markers, bronchial hyperresponsiveness (BHR) and symptoms in at-risk subgroups as defined from measurements of markers made shortly after the start of training.Entities:
Keywords: Airway inflammation; Airway resistance; Apprentices; Bakers; Bronchial challenge test; Fractional exhaled nitric oxide; Hairdressers; Occupational asthma
Mesh:
Substances:
Year: 2018 PMID: 29996808 PMCID: PMC6042364 DOI: 10.1186/s12890-018-0674-9
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Baseline association between risk groups and the personal characteristics of the 318 subjects (median [interquartile range], % (n))
| NO group | Eosinophil count group | Airway responsiveness FEV1 group | Airway responsiveness resistance group | |||||
|---|---|---|---|---|---|---|---|---|
| +a | -a | +b | -b | +c | -c | +d | -d | |
| Sex: male 55.3% (176) | 58.7% (27) | 54.8% (149) | 63.6% (28) | 54.0% (148) | 56.8% (25) | 55.1% (151) | 55.6% (15) | 55.3% (161) |
| Atopic disposition 37.1% (118) | 41.3% (19) | 36.4% (99) | 47.7% (21) | 35.4% (97) | 47.7% (21) | 35.4% (97) | 33.3% (9) | 37.5% (109) |
| p = 0.12 | ||||||||
| Atopic disease 18.2% (58) | 15.2% (7) | 18.8% (51) |
|
| 15.9% (7) | 18.6% (51) | 22.2% (6) | 17.9% (52) |
|
| ||||||||
| Personal atopy based on SPT | ||||||||
| ≥ 1 positive response 32.1% (102) |
|
|
|
|
|
|
|
|
| Degree of sensitization | ||||||||
| 0 positive response |
|
|
|
|
|
| 44.4% (12) | 65.1% (188) |
| 1 to 2 positive responses |
|
|
|
|
|
| 29.6% (8) | 19.0% (55) |
| ≥ 3 positive responses |
|
|
|
|
|
| 25.9% (7) | 15.9% (46) |
|
|
| |||||||
| Training track | ||||||||
| Bakery- Pastry making 60.1% (191) | 69.6% (32) | 58.5% (159) | 65.9% (29) | 59.1% (162) | 54.6% (24) | 61.0% (167) | 74.1% (20) | 58.8% (171) |
| Hairdressing 39.9% (127) | 30.4% (14) | 41.5% (113) | 34.1% (15) | 40.9% (112) | 45.5% (20) | 39.1% (107) | 25.9% (7) | 41.2% (120) |
| p = 0.12 | ||||||||
| Tobacco usage status | ||||||||
| Non smoker 49.7% (158) | 63.0% (29) | 47.4% (129) | 54.6% (24) | 48.9% (134) | 47.7% (21) | 50.0% (137) | 33.3% (9) | 51.2% (149) |
| Current smoker 46.2% (147) | 32.6% (15) | 48.5% (132) | 43.2% (19) | 46.7% (128) | 50.0% (22) | 45.6% (125) | 63.0% (17) | 44.7% (130) |
| Past smoker 4.1% (13) | 4.4% (2) | 4.0% (11) | 2.3% (1) | 4.4% (12) | 2.3% (1) | 4.4% (12) | 3.7% (1) | 4.1% (12) |
| Baseline FEV1 | ||||||||
| > 80.0% 87.1% (277) | 91.3% (42) | 86.4% (235) | 81.8% (36) | 88.0% (241) |
|
| 92.6% (25) | 86.6% (252) |
| > 70.0 and < 80.0% 12.3% (39) | 8.7% (4) | 12.9% (35) | 15.9% (7) | 11.7% (32) |
|
| 7.4% (2) | 12.7% (37) |
| < 70.0% 0.6% (2) | 0 | 0.7% (2) | 2.3% (1) | 0.4% (1) |
|
| 0 | 0.7% (2) |
aNO Group +: subjects with a baseline FeNO level > 27 ppb; −: subjects with a baseline FeNO level < 27 ppb
bEosinophil Count Group +: subjects with a baseline percentage of eosinophils > 1% in the nasal lavage; −: subjects with no eosinophils at baseline
cAirway Responsiveness FEV1 Group +: subjects with a baseline decrease in FEV1 of 15% or more during the MBC test; −: subjects with a baseline FEV1 decrease < 15%
dAirway Responsiveness Resistance Group +: subjects with a baseline increase in resistance of 50% or more between 4 and 16 Hz; −: subjects with a baseline increase in resistance of < 50%
p: p-value of the test comparing the presence or level of a marker in the +risk group and -risk group
Baseline associations between risk groups and airway inflammation and responsiveness markers among the 318 subjects (median [interquartile range], % (n))
| NO group | Eosinophil count group | Airway responsiveness FEV1 group | Airway responsiveness resistance group | |||||
|---|---|---|---|---|---|---|---|---|
| +a | -a | +b | -b | +c | -c | +d | -d | |
| Rhinoconjunctivitis-like symptoms | 6.5% (3) | 9.2% (25) | 9.1% (4) | 8.8% (24) | 4.6% (2) | 9.5% (26) | 11.1% (3) | 8.6% (25) |
| Asthma-like symptoms | 6.5% (3) | 1.8% (5) | 4.6% (2) | 2.2% (6) | 0.0% (0) | 2.9% (8) | 3.7% (1) | 2.4% (7) |
| MBC test | ||||||||
| (Pre – post-test)/pretest FEV1[%] |
|
| −7.5 [− 12.2;-3.6] | −6.2 [− 11.2;-3.6] |
|
|
|
|
| e | ||||||||
| (Post– pretest)/pretest Rrs4–16 [%] | 17.7 [10.7;34.0] | 15.8 [6.5;29.0] | 14.4 [5.3;28.3] | 16.1 [6.8;29.7] |
|
|
|
|
| e | ||||||||
| Eosinophil count | ||||||||
| Eosinophil count < 1 86.2% (274) |
|
|
|
| 81.8% (36) | 86.9% (238) | 88.9% (24) | 86.0% (250) |
|
| e | |||||||
| Eosinophil count [%] if ≥1% |
|
|
|
| 37.0 [15.1;65.7] | 11.9 [4.9;23.3] | 60.0 [16.7;80.0] | 12.0 [5.0;26.6] |
| e | ||||||||
| FeNO [ppb] |
|
|
|
|
|
|
|
|
| e |
| |||||||
aNO Group +: subjects with a baseline FeNO level > 27 ppb; −: subjects with a baseline FeNO level < 27 ppb
bEosinophil Count Group +: subjects with a baseline percentage of eosinophils > 1% in the nasal lavage; −: subjects with no eosinophils at baseline
cAirway Responsiveness FEV1 Group +: subjects with a baseline decrease in FEV1 of 15% or more during the MBC test; −: subjects with a baseline FEV1 decrease < 15%
dAirway Responsiveness Resistance Group +: subjects with a baseline increase in resistance of 50% or more between 4 and 16 Hz; −: subjects with a baseline increase in resistance < 50%
enot tested because associations exist for structural reasons
p: p-value of the test comparing the presence or level of a marker in the +risk group and-risk group
Associations between risk groups and the evolution of airway inflammation and responsiveness markers among the 318 subjects
| Evolution | At inclusion | |||||||
|---|---|---|---|---|---|---|---|---|
| NO Group | Eosinophil Count Group | Airway Responsiveness FEV1 Group | Airway Responsiveness Resistance Group | |||||
| Number of subjects | +a | -a | +b | -b | +c | -c | +d | -d |
| Proportion of subjects with rhinoconjunctivitis-like symptomse | ||||||||
| | ||||||||
| Model- predicted value | 29.1% | 29.0% | 32.5% | 28.4% | 25.2% | 29.8% | 23.2% | 29.7% |
| OR(p) | 1.01 (0.98) f | 1.4 (0.48) f | 0.70 (0.39) f | 0.59 (0.34) f | ||||
| Proportion of subjects with asthma-like symptomse | ||||||||
| p-value for interaction | ||||||||
| Model- predicted value | 6.5% | 8.6% | 6.3% | 8.7% | 8.8% | 8.4% | 6.3% | 8.7% |
| OR(p) | 0.65 (0.56) f | 0.62 (0.50) f | 1.08 (0.90) f | 0.62 (0.55) f | ||||
| Percentage decrease during MBC test - FEV1[%]g | ||||||||
| p-value for interaction | ||||||||
| Model- predicted value | 9.7% | 9.3% | 8.9% | 9.4% |
|
| 10.8% | 9.2% |
| Difference (p) | 0.44 (0.67) h | 0.47 (0.64) h |
| 1.63 (0.19) h | ||||
| Percentage increase during MBC test - resistance[%]g | ||||||||
| p-value for interaction | ||||||||
| Model- predicted value | 22.1% | 18.9% | 18.9% | 19.4% | 23.0% | 18.7% | 25.2% | 18.5% |
| Difference (p) | 3.28 (0.17) h | −0.58 (0.80) h | 4.24 (0.06) h | 6.8 (0.052) f | ||||
| Proportion of subjects with a possible asthmae | ||||||||
| p-value for interaction | Not estimable | |||||||
| Model- predicted value | 0.9% | 1.7% | 2.0% | 1.6% |
|
| 3.3% | 1.5% |
| OR(p) | 0.50 (0.57) f | 1.30 (0.79) f |
| 2.53 (0.36) f | ||||
| Proportion of subjects with eosinophil count ≥1%e | ||||||||
| p-value for interaction | p = 0.61 | p = 0.50 | ||||||
| Model- predicted value |
|
|
|
| 13.4% | 11.5% | 10.5% | 12.0% |
| OR(p) |
|
| 1.22 (0.497) h | 0.84 (0.66) h | ||||
| FeNO level [ppb] g | ||||||||
| p-value for interaction | p = 0.43 | p = 0.33 | ||||||
| Model- predicted value |
|
|
|
|
|
|
|
|
| Ratio (p) |
|
|
|
| ||||
aNO Group +: subjects with a baseline FeNO level > 27 ppb; −: subjects with a baseline FeNO level < 27 ppb
bEosinophil Count Group +: subjects with a baseline percentage of eosinophils > 1% in the nasal lavage; −: subjects without eosinophils at baseline
cAirway Responsiveness FEV1 Group +: subjects with a baseline FEV1 decrease of 15% or more during the MBC test; −: subjects with a baseline FEV1 decrease < 15%
dAirway Responsiveness Resistance Group +: subjects with a baseline increase in resistance of 50% or more between 4 and 16 Hz; −: subjects with a baseline resistance increase < 50%
eLogistic regression; symptom models adjusted for sex, degree of sensitization, tobacco usage status, training track, and visit; eosinophil count model adjusted for degree of sensitization, training track, and visit
fIn visits 2,3,4 excluding the interaction between the risk group at inclusion and the number of the visit on the evolution of the marker
gLinear regression; adjustment for sex, height, degree of sensitization, tobacco usage status, training track, and visit
hIn visits 1, 2, 3, 4 excluding interaction between the risk group at inclusion and the number of the visit on the evolution of the marker
p-value for interaction: p-value for interaction between the baseline risk group and the number of the visit on the evolution of the marker
Fig. 1Evolution of FeNO over the visits for each baseline risk group. p-interaction: p-value for interaction between the baseline risk group and the number of the visit on the evolution of the FeNO values. NO: Fractional exhaled Nitric Oxide group; Eosino: Eosinophil Count group; HR: Airway Responsiveness FEV1 group; Resist: Airway Responsiveness Resistance group